IR-61 Improves Voiding Function via Mitochondrial Protection in Diabetic Rats

Jianwu Wang, Linyong Dai, Xiaofeng Yue, Chongxing Shen, Tong Li, Lei Long, Yi Zhi, Yawei Wang, Gufang Shen, Chunmeng Shi, Yunsheng Liu, Qiang Fang, Weibing LiFrontiers in Pharmacology 2021 · DOI

Abstract

Diabetic bladder dysfunction (DBD) is a prevalent complication of diabetes with limited treatment options. This study investigates IR-61, a novel heptamethine cyanine dye, as a potential therapy. We found that IR-61 accumulates specifically in the mitochondria of bladder smooth muscle cells (BSMCs) in diabetic rats. Treatment with IR-61 significantly improved bladder function, mitigated pathological changes in bladder smooth muscle, and reduced oxidative stress-induced apoptosis by activating the Nrf2 antioxidant pathway.

Introduction

Diabetic bladder dysfunction (DBD) affects nearly 50% of diabetic patients, significantly impacting quality of life. The condition typically progresses from an early overactive phase to a late-stage "myogenic" failure, characterized by impaired bladder emptying and increased residual volume. Chronic hyperglycemia triggers the production of reactive oxygen species (ROS), which damage the mitochondria of bladder smooth muscle cells (BSMCs), leading to energy failure and apoptosis. Current therapies often fail to address this underlying mitochondrial damage.

Targeted Mitochondrial Accumulation of IR-61

IR-61 is a near-infrared (NIR) fluorescent dye known for its antioxidant properties and affinity for mitochondria. Using NIR imaging and confocal microscopy, the researchers tracked the biodistribution of IR-61 in a streptozotocin (STZ)-induced diabetic rat model.

Biodistribution and mitochondrial localization of IR-61. (A, B) NIR imaging shows IR-61 accumulation in the bladder (B) over time. (C, D) Confocal microscopy confirms IR-61 (red) co-localizes with Mito Tracker Green in BSMCs.

As shown in Figure 1, IR-61 preferentially accumulates in the bladder of diabetic rats and specifically targets the mitochondria within BSMCs. This "homing" ability makes it an ideal candidate for targeted antioxidant therapy.

Functional Restoration of Bladder Performance

To evaluate the therapeutic efficacy of IR-61, filling cystometry was performed. Diabetic rats typically show significantly reduced voiding efficiency (VE) and increased residual volume (RV).

IR-61 treatment restores Voiding Efficiency (VE) in diabetic rats.

Treatment with IR-61 significantly increased VE (Figure 3) and maximum voiding pressure while decreasing RV. These functional improvements were accompanied by structural rescue; IR-61 prevented the thinning of the bladder wall and reduced fibrosis-like shifts in the muscle-to-collagen ratio.

Molecular Mechanism: Nrf2 Pathway Activation

The protective effects of IR-61 are mediated through the activation of the Nrf2 antioxidant signaling pathway. IR-61 promotes the dissociation of Nrf2 from its inhibitor, Keap1, leading to the upregulation of protective enzymes such as HO-1 and SOD. This reduces ROS levels and stabilizes mitochondrial integrity, thereby blocking the intrinsic apoptotic pathway (evidenced by decreased BAX and cleaved Caspase-9).

Conclusion

IR-61 effectively alleviates DBD in rats by protecting BSMC mitochondria from oxidative stress. Its ability to target mitochondria and activate the Nrf2 pathway suggests it could be a potent "smart" therapy for diabetic complications involving mitochondrial dysfunction.

Summary updated

Abstract

Diabetic bladder dysfunction (DBD) afflicts nearly half of diabetic patients, but effective treatment is lacking. In this study, IR-61, a novel heptamethine cyanine dye with potential antioxidant effects, was investigated to determine whether it can alleviate DBD. Rats were intraperitoneally injected with IR-61 or vehicle after diabetes was induced with streptozotocin. Before evaluating the effects of IR-61 in improving DBD by filling cystometry, we detected its distribution in tissues and subcellular organelles by confocal fluorescence imaging. Near infrared (NIR) imaging showed that IR-61 could accumulate at high levels in the bladders of diabetic rats, and confocal images demonstrated that it was mainly taken up by bladder smooth muscle cells (BSMCs) and localized in mitochondria. Then, filling cystometry illustrated that IR-61 significantly improved the bladder function of diabetic rats. The histomorphometry results showed that IR-61 effectively mitigated the pathological changes in bladder smooth muscle (BSM) in diabetic rats. Furthermore, IR-61 remarkably reduced the number of apoptotic BSMCs and the unfavorable expression of proteins related to the mitochondrial apoptotic pathway (Bcl-2, BAX, Cytochrome C, and cleaved Caspase-9) in diabetic rats. Moreover, the frozen section staining and transmission electron microscopy results proved that IR-61 significantly reduced the reactive oxygen species (ROS) levels and prevented the mitochondrial mass and morphology damage in the BSM of diabetic rats. In addition, IR-61 upregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and its associated antioxidant proteins in the BSM of diabetic rats. Together, these results indicate that IR-61 can improve the voiding function of rats with DBD by protecting the mitochondria of BSMCs from oxidative stress, which is possibly mediated through the activation of the Nrf2 pathway.
BibTeX
@inproceedings{wang2021ir,
  author = {Jianwu Wang and Linyong Dai and Xiaofeng Yue and Chongxing Shen and Tong Li and Lei Long and Yi Zhi and Yawei Wang and Gufang Shen and Chunmeng Shi and Yunsheng Liu and Qiang Fang and Weibing Li},
  title = {{IR-61 Improves Voiding Function via Mitochondrial Protection in Diabetic Rats}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.608637},
}
Figure